Verona pharma to announce top-line data from phase 3 enhance-2 trial of nebulized ensifentrine for copd

Second quarter 2022 financial results and corporate update second quarter 2022 financial results and corporate update

VRNA Ratings Summary

VRNA Quant Ranking